IL75280A0 - Lymphokine in pure form,its manufacture,pharmaceutical compositions containing it,monoclonal antibodies thereto,their production and hybridoma cell lines used therefor - Google Patents

Lymphokine in pure form,its manufacture,pharmaceutical compositions containing it,monoclonal antibodies thereto,their production and hybridoma cell lines used therefor

Info

Publication number
IL75280A0
IL75280A0 IL75280A IL7528085A IL75280A0 IL 75280 A0 IL75280 A0 IL 75280A0 IL 75280 A IL75280 A IL 75280A IL 7528085 A IL7528085 A IL 7528085A IL 75280 A0 IL75280 A0 IL 75280A0
Authority
IL
Israel
Prior art keywords
monoclonal antibodies
cell lines
hybridoma cell
human mif
lymphokine
Prior art date
Application number
IL75280A
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of IL75280A0 publication Critical patent/IL75280A0/en
Priority to IL91476A priority Critical patent/IL91476A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

The invention relates to purified human macrophage migration inhibitory factor (human MIF) and its individual proteins, to a process for the purification of human MIF and for the isolation of its individual proteins, to monoclonal antibodies against human MIF, derivatives thereof, processes for the preparation of these antibodies and derivatives thereof, hybridoma cell lines which produce these antibodies, processes for the preparation of said hybridoma cell lines, and to the use of the monoclonal antibodies and derivatives thereof for the qualitative and quantitative determination of human MIF in biological fluids and on cell surfaces, and to the use of the monoclonal antibodies for the purification of human MIF. Human MIF and monoclonal antibodies against human MIF are important for the diagnosis and therapy of immunoregulatory disorders and chronic inflammatory disorders.
IL75280A 1984-05-24 1985-05-22 Lymphokine in pure form,its manufacture,pharmaceutical compositions containing it,monoclonal antibodies thereto,their production and hybridoma cell lines used therefor IL75280A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL91476A IL91476A0 (en) 1984-05-24 1989-08-30 Monoclonal antibodies to human macrophage migration inhibition factor(mif),its preparation and its use in the determination of human mif

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH255784 1984-05-24
CH378684 1984-08-07
CH544684 1984-11-14
CH51285 1985-02-05

Publications (1)

Publication Number Publication Date
IL75280A0 true IL75280A0 (en) 1985-09-29

Family

ID=27427909

Family Applications (1)

Application Number Title Priority Date Filing Date
IL75280A IL75280A0 (en) 1984-05-24 1985-05-22 Lymphokine in pure form,its manufacture,pharmaceutical compositions containing it,monoclonal antibodies thereto,their production and hybridoma cell lines used therefor

Country Status (8)

Country Link
EP (1) EP0162812B1 (en)
JP (3) JPH0672158B2 (en)
AT (1) ATE93869T1 (en)
DE (1) DE3587553D1 (en)
DK (1) DK171646B1 (en)
ES (3) ES8702950A1 (en)
IE (1) IE60450B1 (en)
IL (1) IL75280A0 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8623850D0 (en) * 1986-10-03 1986-11-05 Ciba Geigy Ag Lymphokine related peptide
EP0263072B1 (en) * 1986-10-03 1994-03-23 Ciba-Geigy Ag Novel lymphokine related peptides
WO1990011301A1 (en) * 1989-03-17 1990-10-04 Genetics Institute, Inc. Human macrophage migration inhibitory factor
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
US5107906A (en) * 1989-10-02 1992-04-28 Swenson Paul F System for fast-filling compressed natural gas powered vehicles
US5149544A (en) * 1989-11-13 1992-09-22 Research Corporation Technologies, Inc. Method of inhibiting progenitor cell proliferation
DE69435303D1 (en) * 1993-05-17 2010-09-02 Cytokine Pharmasciences Inc HE TREATING DISEASES IN WHICH A CYTOK
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
AU2001238677A1 (en) * 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
DE10121255A1 (en) 2001-04-30 2002-11-07 Switch Biotech Ag Use of alpha 1-antichymotrypsin polypeptide or nucleic acids encoding the polypeptide, or of a cell expressing the polypeptide, or of antibody against the polypeptide, for diagnosing, treating or preventing poorly-healing wounds
UY27304A1 (en) 2001-05-24 2002-12-31 Avanir Pharmaceuticals INHIBITORS OF THE INHIBITOR FACTOR OF MIGRATION OF MACROPHAGES AND METHODS FOR IDENTIFICATION
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
BRPI0609382A2 (en) 2005-03-24 2010-03-30 Avanir Pharmaceuticals thienopyridinone derivatives as inhibitors of macrophage migration inhibitory factor
CN100457895C (en) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 Rat antihuman macrephage migration inhibiting factor monoclone antibody and its application
WO2013050453A1 (en) * 2011-10-07 2013-04-11 Baxter Healthcare S.A. Oxmif as a diagnostic marker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2755363C3 (en) * 1977-12-12 1983-12-01 R & Z Biologicals Beteiligungsgesellschaft mbH, 4050 Mönchengladbach Test method for diagnosing malignancies
US4299814A (en) * 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
JPS5939832A (en) * 1982-08-28 1984-03-05 Ajinomoto Co Inc Monoclonal antibody and preparation and use thereof
DD230876A1 (en) * 1983-05-09 1985-12-11 Akad Wissenschaften Ddr PROCESS FOR OBTAINING MONOCLONAL ANTIBODY AGAINST HUMAN MIF

Also Published As

Publication number Publication date
ES557072A0 (en) 1987-08-01
IE60450B1 (en) 1994-07-13
DK171646B1 (en) 1997-03-03
ES557071A0 (en) 1988-02-16
JPH06217789A (en) 1994-08-09
JPS60248617A (en) 1985-12-09
EP0162812A3 (en) 1988-04-20
DK229985A (en) 1985-11-25
DE3587553D1 (en) 1993-10-07
IE851295L (en) 1985-11-24
ATE93869T1 (en) 1993-09-15
JPH0672158B2 (en) 1994-09-14
DK229985D0 (en) 1985-05-23
ES8801852A1 (en) 1988-02-16
JPH0770192A (en) 1995-03-14
JPH0780915B2 (en) 1995-08-30
ES8801850A1 (en) 1987-08-01
EP0162812A2 (en) 1985-11-27
ES8702950A1 (en) 1987-01-16
EP0162812B1 (en) 1993-09-01
ES543391A0 (en) 1987-01-16
JPH07108915B2 (en) 1995-11-22

Similar Documents

Publication Publication Date Title
IL75280A0 (en) Lymphokine in pure form,its manufacture,pharmaceutical compositions containing it,monoclonal antibodies thereto,their production and hybridoma cell lines used therefor
Van Damme et al. Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6.
Van Damme et al. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor.
NO165556C (en) MONOCLONAL ANTIBODY AND DERIVATIVES THEREOF WITH HIGH EFFICIENCY TO HUMAN PURE AND STRUCTURALLY LIKE PURE IN IN VITRO APPLICATION.
Van Snick et al. Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas.
Muraguchi et al. T cell-replacing factor-(TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF.
Van Damme et al. The role of interferon-beta 1 and the 26-kDa protein (interferon-beta 2) as mediators of the antiviral effect of interleukin 1 and tumor necrosis factor.
AU578050B2 (en) Desulfatohirudins, the preparation thereof and pharmaceutical compositions containing them
ZA891861B (en) Monoclonal antibodies
ATE245699T1 (en) RECOMBINANT PGP3, METHOD FOR THE PRODUCTION THEREOF, AND ITS USE IN DIAGNOSIS AND THERAPY
Chen et al. Production of osteoclast‐activating factor by normal human peripheral blood rosetting and nonrosetting lymphocytes
DK118682A (en) ANIGIOTROPINES FROM LEUCOCYTES AND INFLAMMATION TISSUE AND PROCEDURES FOR PRODUCING THEREOF
Van Damme et al. Characterization of granulocyte chemotactic activity from human cytokine-stimulated chondrocytes as interleukin 8
EP0265384A3 (en) Monoclonal antibodies to a colony stimulating factor
DE3855747D1 (en) BIOLOGICAL MATERIALS, THEIR PRODUCTION AND USE IN THERAPY
Hardwicke et al. Human α1-glycoproteins Separation from pathological urine and examination by immunological and electrophoretic methods
AU7151087A (en) Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies
NO174110C (en) Monoclonal antibody for use in vitro for the diagnosis of malignant tumor or acute inflammatory diseases and specific for N-acetyl neuraminic acid in hybridomas producing the antibody
Nishihara et al. Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide
Kishimoto et al. Polymorphism of submandibular-sublingual salivary proteins which promote adhesion of Streptococcus mutans serotype-c strains to hydroxyapatite
Knudsen et al. Elevated intracellular cAMP levels inhibit interleukin-1 production by the tumour cell line U937
Van Damme et al. IDENTIFICATION OF THE HUMAN 26-kD PROTEIN, INTERFERON 02 (IFN-N2), AS AB CELL HYBRIDOMA/PLASMACYTOMA GROWTH FACTOR INDUCED BY INTERLEUKIN 1 AND TUMOR NECROSIS FACTOR
ATE229983T1 (en) MASPIN- A NEW SERPIN WITH TUMOR SUPPRESSING ACTIVITY
Lamkin et al. Purification and Partial Characterization of a M r 52,000 Glycoprotein from Human Cancer Ascites Fluid Which Stimulates Bone Resorption in Vitro
Kull Jr et al. Macrophage cytotoxin: Sources and mechanism